EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSATEG00000019798
Gene Symbol: ATP1B3A
3 Cross references
229 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3b

Ensembl ID : ENSATEG00000019311
Gene Symbol: ATP1B3B
2 Cross references
230 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSATEG00000023130
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSATEG00000000873
Gene Symbol: BCL2L1
3 Cross references
229 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSATEG00000001038
Gene Symbol: BCL2L10
3 Cross references
129 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSATEG00000020566
Gene Symbol: BCR
2 Cross references
209 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSATEG00000000600
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSATEG00000002564
Gene Symbol: LOC113169995
2 Cross references
405 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSATEG00000002691
Gene Symbol: LOC113170078
2 Cross references
405 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSATEG00000004026
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSATEG00000021176
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSATEG00000005046
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).